RESUMEN
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Asunto(s)
Antifúngicos/uso terapéutico , Candidiasis/tratamiento farmacológico , Fluconazol/uso terapéutico , Fungemia/tratamiento farmacológico , Péptidos Cíclicos/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anidulafungina , Antifúngicos/efectos adversos , Candida/aislamiento & purificación , Candidiasis/mortalidad , Método Doble Ciego , Equinocandinas , Femenino , Fluconazol/efectos adversos , Fungemia/mortalidad , Humanos , Infusiones Intravenosas , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Péptidos Cíclicos/efectos adversos , Resultado del TratamientoRESUMEN
Evidence-based guidelines for the management of patients with blastomycosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous management guidelines published in the April 2000 issue of Clinical Infectious Diseases. The guidelines are intended for use by health care providers who care for patients who have blastomycosis. Since 2000, several new antifungal agents have become available, and blastomycosis has been noted more frequently among immunosuppressed patients. New information, based on publications between 2000 and 2006, is incorporated in this guideline document, and recommendations for treating children with blastomycosis have been noted.
Asunto(s)
Antifúngicos , Blastomicosis , Humanos , Antifúngicos/uso terapéutico , Blastomicosis/diagnóstico , Blastomicosis/tratamiento farmacológico , Estados UnidosRESUMEN
We describe a case of recurring Candida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.
Asunto(s)
Antifúngicos/farmacología , Candida glabrata/efectos de los fármacos , Equinocandinas/farmacología , Fungemia/tratamiento farmacológico , Glucosiltransferasas/genética , Proteínas de la Membrana/genética , Mutación , Anciano , Antifúngicos/uso terapéutico , Candidiasis/tratamiento farmacológico , Candidiasis/microbiología , Caspofungina , Farmacorresistencia Fúngica/genética , Equinocandinas/uso terapéutico , Resultado Fatal , Femenino , Proteínas Fúngicas/genética , Fungemia/microbiología , Humanos , Lipopéptidos , Pruebas de Sensibilidad MicrobianaRESUMEN
The ideal antifungal agent remains an elusive goal for treatment of life-threatening systemic fungal infections. Such an agent would have broad antifungal activity, low rates of resistance, flexible routes of administration, few associated adverse events, and limited drug-drug interactions. Only three of the seven classes of antifungal agents currently available are suitable for treatment of systemic infection: the polyenes, the azoles, and the echinocandins. None match all the characteristics of an ideal agent, the Holy Grail of antifungal therapy. Academia and industry need to collaborate in the search for new lead antifungal compounds using traditional screening methods as well as the new pharmacogenomics methods. Enhancing efficacy and reducing toxicity of the currently available therapeutic agents is also another important avenue of study. As an example, the Mycosis Research Center at the University of Mississippi Medical Center has identified pyogenic polyenes in commercial preparations of amphotericin B deoxycholate which correlate with infusion related toxicities. A highly purified formulation of amphotericin B appears promising, with a better therapeutic index compared to its parent compound as evidenced by results of in vitro and in vivo studies reviewed in this presentation.
Asunto(s)
Antifúngicos/aislamiento & purificación , Antifúngicos/uso terapéutico , Micosis/tratamiento farmacológico , Anfotericina B/efectos adversos , Anfotericina B/aislamiento & purificación , Anfotericina B/farmacología , Antifúngicos/efectos adversos , Antifúngicos/química , Azoles/química , Azoles/aislamiento & purificación , Azoles/farmacología , Contaminación de Medicamentos , Diseño de Fármacos , Hongos/efectos de los fármacos , Hongos/genética , Hongos/patogenicidad , Genómica , Humanos , Micosis/inmunología , ProteómicaRESUMEN
BACKGROUND AND PURPOSE: The rate of cerebrovascular events within the stroke belt, a geographic area defined in the Southeastern United States, exceeds that of the rest of the nation. Despite evaluation of multiple risk factors for this disparity, specific causes for the stroke belt have not been elucidated. More than 45 years ago, the US Public Health Service and US Navy cooperative skin-testing program (1958-1965) documented adolescent exposure to Histoplasma capsulatum. Our purpose was to evaluate the association between exposure to Histoplasma capsulatum and subsequent development of stroke. METHODS: A cross-sectional study of stroke in a cohort of US Navy veterans was designed to assess our hypothesis. Medical records from 23,795 men who participated in the cooperative skin-testing program and who received medical care at Veterans Administration Hospitals and Clinics were reviewed. A logistic regression model was used to estimate the odds ratio of stroke while controlling for multiple covariates. Because of the large number of possible risk factors for stroke, propensity scores were used to reduce bias. RESULTS: The adjusted odds ratio for stroke in veterans exposed to Histoplasma capsulatum during adolescence was 1.34 (95% confidence interval: 1.1-1.6; P = .0033). The increased risk was independent of traditional cerebrovascular event risk factors. Less frequent risk factors (atrial fibrillation, coronary heart disease, rheumatic heart disease, and prosthetic cardiac valvular replacement) were not controlled in this model. CONCLUSION: Exposure to Histoplasma capsulatum during adolescence was associated with an increased risk of stroke.
Asunto(s)
Histoplasmosis/epidemiología , Accidente Cerebrovascular/microbiología , Adolescente , Adulto , Isquemia Encefálica/epidemiología , Estudios de Casos y Controles , Estudios de Cohortes , Comorbilidad , Estudios Transversales , Humanos , Modelos Logísticos , Estudios Longitudinales , Masculino , Oportunidad Relativa , Estudios Retrospectivos , Medición de Riesgo , Accidente Cerebrovascular/epidemiología , Estados Unidos/epidemiología , VeteranosRESUMEN
Guidelines for the management of patients with sporotrichosis were prepared by an Expert Panel of the Infectious Diseases Society of America and replace the guidelines published in 2000. The guidelines are intended for use by internists, pediatricians, family practitioners, and dermatologists. They include evidence-based recommendations for the management of patients with lymphocutaneous, cutaneous, pulmonary, osteoarticular, meningeal, and disseminated sporotrichosis. Recommendations are also provided for the treatment of sporotrichosis in pregnant women and in children.
Asunto(s)
Antifúngicos , Esporotricosis , Femenino , Humanos , Masculino , Embarazo , Antifúngicos/administración & dosificación , Complicaciones del Embarazo , Esporotricosis/diagnóstico , Esporotricosis/tratamiento farmacológico , Estados UnidosRESUMEN
BACKGROUND: Intestinal parasites are difficult to eradicate in tropical climates where poor sanitation exists. In addition, pharmaceutical stability is poor making traditional three day dosing for the treatment of A. lumricoides challenging. METHODS: Single 100 mg doses of mebendazole were administered to persons living along Amazon tributaries in Northeastern Peru. Directly-observed treatment was repeated at 3-month intervals over a 2-year period in a single treatment village. Treatment was repeated at 12-month intervals in the remaining (control) villages. Treatment was accompanied by a regimen of multivitamins with iron to be taken daily for 14 days after each treatment. Subjects were screened for ova and parasites prior to treatment and at 1-year intervals. In addition to A. lumbricoides, other parasites found on screening were recorded. RESULTS: Treatment resulted in a 92.5% cure rate for A. lumbricoides at the 2-year assessment. Growth and development assessments demonstrated fewer individuals below the 3 percentile for age-adjusted measurements when treated quarterly. CONCLUSIONS: Based on these limited data, single low-dose mebendazole administered quarterly appears to have a positive effect on the health of isolated village populations in the Amazon River basin.
Asunto(s)
Antinematodos/administración & dosificación , Antinematodos/uso terapéutico , Ascariasis/tratamiento farmacológico , Mebendazol/administración & dosificación , Mebendazol/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Amazona/parasitología , Animales , Antinematodos/farmacología , Ascaris lumbricoides/efectos de los fármacos , Niño , Preescolar , Protocolos Clínicos , Esquema de Medicación , Femenino , Humanos , Lactante , Masculino , Mebendazol/farmacología , Persona de Mediana Edad , Recuento de Huevos de Parásitos , PerúRESUMEN
A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other than Candida krusei in adults without neutropenia. A total of 219 patients met criteria for a modified intent-to-treat analysis. The groups were similar except that those who were treated with fluconazole plus placebo had a higher mean (+/- standard error) Acute Physiology and Chronic Health Evaluation II score (16.8+/-0.6 vs. 15.0+/-0.7; P=.039). Success rates on study day 30 by Kaplan-Meier time-to-failure analysis were 57% for fluconazole plus placebo and 69% for fluconazole plus AmB (P=.08). Overall success rates were 56% (60 of 107 patients) and 69% (77 of 112 patients; P=.043), respectively; the bloodstream infection failed to clear in 17% and 6% of subjects, respectively (P=.02). In nonneutropenic subjects, the combination of fluconazole plus AmB was not antagonistic compared with fluconazole alone, and the combination trended toward improved success and more-rapid clearance from the bloodstream.
Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Candidiasis/tratamiento farmacológico , Fluconazol/uso terapéutico , Fungemia/tratamiento farmacológico , Adulto , Anfotericina B/efectos adversos , Antifúngicos/efectos adversos , Candida/efectos de los fármacos , Candidiasis/fisiopatología , Cateterismo , Método Doble Ciego , Quimioterapia Combinada , Femenino , Fluconazol/efectos adversos , Fungemia/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Neutropenia/etiología , Resultado del TratamientoRESUMEN
Blastomycosis is an endemic mycoses in the central United States caused by a dimorphic fungus, Blastomyces dermatitidis, that exists in nature in mycelial phase and converts to yeast phase at body temperature. The organism may produce epidemics of infection following a point source of infection or sporadic endemic infection. Blastomycosis can be a subclinical illness with subsequent protection against progressive infection afforded by cellular immune mechanisms, but it may present with progressive disease with either pulmonary or extrapulmonary disease or both. Itraconazole has been shown to be the drug of choice for both infections, except in cases of life-threatening infection when amphotericin B should be used.
Asunto(s)
Blastomicosis , Blastomyces/patogenicidad , Blastomicosis/diagnóstico , Blastomicosis/tratamiento farmacológico , Blastomicosis/epidemiología , Blastomicosis/patología , Enfermedades Óseas/microbiología , Enfermedades Óseas/patología , Protocolos Clínicos , Enfermedades Urogenitales Femeninas/microbiología , Enfermedades Urogenitales Femeninas/patología , Humanos , Enfermedades Pulmonares Fúngicas/epidemiología , Enfermedades Pulmonares Fúngicas/terapia , Enfermedades Urogenitales Masculinas , Onygenales/clasificación , Onygenales/genética , Onygenales/patogenicidad , Enfermedades de la Piel/microbiología , Enfermedades de la Piel/patologíaRESUMEN
STUDY OBJECTIVE: To evaluate the toxicity of amphotericin B deoxycholate formulations. DESIGN: In vitro experiment. SETTING: University research center. MATERIAL: Human mononuclear THP-1 cells. INTERVENTION: The human mononuclear cells were exposed in vitro for 2 hours to the following deoxycholate formulations of amphotericin B, in 2.5- and 5-micro/ml concentrations: Apothecon, Pharmacia, Sigma, Gensia, Pharma-Tek, and VHA. MEASUREMENTS AND MAIN RESULTS: Toxicity of the amphotericin B formulations were assessed by measuring interleukin (IL)-1beta expression in an in vitro model. Amphotericin B content was measured by enzyme-linked immunosorbent assay (ELISA), and amphotericin A and B contents were assessed by spectrophotometry. Endotoxin contamination was evaluated in all reagents. Expression of IL-1beta from Sigma, Pharmacia, and Pharma-Tek formulations was increased approximately 250%, 50%, and 25%, respectively, compared with amphotericin A. Amphotericin B content of Sigma, Pharmacia, Pharma-Tek, and Gensia formulations, as measured by ELISA, was increased approximately 450%, 200%, 200%, and 100%, respectively, compared with Apothecon. This variation could not be explained by differences in amphotericin A or B content as measured by spectrophotometry. CONCLUSION: Amphotericin B is obtained from a fermentation plant and manufactured as a pharmaceutical at different facilities. Both previous clinical observations and the current in vitro evaluation revealed significant differences among the formulations. Likely, other polyenes or pyrogenic toxins in differing amounts are in these formulations, thus explaining the variability in toxicity observed among the formulations.
Asunto(s)
Anfotericina B/análisis , Antifúngicos/análisis , Ácido Desoxicólico/análogos & derivados , Ácido Desoxicólico/análisis , Polienos/análisis , Anfotericina B/toxicidad , Antifúngicos/toxicidad , Línea Celular , Supervivencia Celular/efectos de los fármacos , Química Farmacéutica , Cromatografía Líquida de Alta Presión , Ácido Desoxicólico/toxicidad , Combinación de Medicamentos , Ensayo de Inmunoadsorción Enzimática , Humanos , Interleucina-1/análisis , Monocitos , EspectrofotometríaRESUMEN
STUDY OBJECTIVE: To determine the effects of amphotericin B deoxycholate and caspofungin on the release of histamine from human peripheral blood cells, mononuclear cells, and mast cells. DESIGN: In vitro cell culture experiments. SETTING: University medical center. MATERIAL: Cultured human mononuclear (THP-1) and mast (HMC-1) cells from five healthy volunteers. MEASUREMENTS AND MAIN RESULTS: The cultured cells were incubated with increasing concentrations of amphotericin B deoxycholate, diphenhydramine, amphotericin B deoxycholate plus diphenhydramine, caspofungin, caspofungin plus diphenhydramine, and the calcium ionophore A23187 for up to 24 hours. Histamine concentrations and histamine N-methyltransferase activity were determined at various time points throughout exposure. Cell viability was assessed by exclusion of erythrocin B. The A23187 increased histamine concentrations from baseline in peripheral blood and HMC-1 cells. No change in histamine concentrations was observed in response to amphotericin B deoxycholate, whereas caspofungin induced a significant increase in histamine release in peripheral blood cells and HMC-1 cells. No change in histamine concentrations was observed in THP-1 cells in response to any pharmacologic agent tested. Similarly, histamine N-methyltransferase activity in peripheral blood was not affected by amphotericin B deoxycholate, but was significantly decreased by caspofungin. CONCLUSION: Amphotericin B deoxycholate does not affect histamine concentrations or histamine N-methyltransferase activity in whole blood or HMC-1 cells, suggesting that the amphotericin B-induced infusion-related reaction is not a histamine-mediated event. Conversely, caspofungin increased histamine concentrations in whole blood and HMC-1 cells and inhibited histamine N-methyltransferase activity. These data suggest that infusion-related reactions associated with caspofungin may be mediated by histamine release secondary to caspofungin.
Asunto(s)
Anfotericina B/farmacología , Antifúngicos/farmacología , Ácido Desoxicólico/farmacología , Agonistas de los Receptores Histamínicos/farmacología , Liberación de Histamina/efectos de los fármacos , Péptidos Cíclicos , Péptidos/farmacología , Caspofungina , Células Cultivadas , Combinación de Medicamentos , Equinocandinas , Histamina/sangre , Histamina N-Metiltransferasa/antagonistas & inhibidores , Histamina N-Metiltransferasa/sangre , Humanos , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/metabolismo , Lipopéptidos , Mastocitos/efectos de los fármacos , Mastocitos/metabolismoAsunto(s)
Diarrea/etiología , Sepsis/diagnóstico , Esplenectomía/efectos adversos , Infecciones Estreptocócicas/diagnóstico , Streptococcus agalactiae , Vómitos/etiología , Resultado Fatal , Femenino , Humanos , Persona de Mediana Edad , Sepsis/etiología , Sepsis/terapia , Infecciones Estreptocócicas/etiología , Infecciones Estreptocócicas/terapiaRESUMEN
The order Actinomycetales includes phylogenetically diverse but morphologically similar aerobic and anaerobic bacteria that exhibit filamentous branching structures which fragment into bacillary or coccoid forms. The aerobic actinomyces are a large, diverse group of gram-positive bacteria including Nocardia, Gordona, Tsukamurella, Streptomyces, Rhodococcus, Streptomycetes, Mycobacteria, and Corynebacteria. The anaerobic genera of medical importance include Actinomyces, Arachnia, Rothia, and Bifidobacterium. Both Actinomyces and Nocardia cause similar clinical syndromes involving the lung, bone and joint, soft tissue, and the central nervous system. The medically important Actinomyces organisms cause infections characterized by chronic progression, abscess formation with fistulous tracts and draining sinuses. Called "great masqueraders," diagnosis of actinomycosis and nocardiosis is often delayed. Once recognized, treatment of these infections requires long courses of parenteral and oral therapy. This review will compare and contrast infections due to Actinomyces and Nocardia.
Asunto(s)
Actinomicosis/diagnóstico , Nocardiosis/diagnóstico , Actinomicosis/tratamiento farmacológico , Actinomicosis/epidemiología , Actinomicosis/microbiología , Celulitis (Flemón)/microbiología , Progresión de la Enfermedad , Humanos , Enfermedades Pulmonares Fúngicas/diagnóstico , Nocardiosis/tratamiento farmacológico , Nocardiosis/epidemiología , Neumonía/microbiología , Enfermedades Cutáneas Infecciosas/microbiologíaRESUMEN
Mannnose-binding lectin (MBL) binds oligosaccharides on the surface of microorganisms to form complexes that activate the complement cascade and facilitate phagocytosis. Teicoplanin and dalbavancin glycopeptide antibiotics possess N-acetyl glucosamine and mannose oligosaccharides that may bind MBL. Pharmaceuticals capable of binding to MBL may decrease clearance of significant pathogens such as yeast. An invasive candidemia murine model was utilized to evaluate differences in survival between mannose- and teicoplanin-treated groups compared to a control group administered normal saline. Three groups of BALB/c mice were injected with Candida albicans ATCC 44858 (1.4 x 10(6) CFU). Pharmaceutical agents were administered 2 h pre-infection and 8 h post-infection. In vivo cumulative survival at 52 h revealed 10%, 30% and 90% survival rates for mice administered mannose, teicoplanin, and saline, respectively. There was 0% survival for mice given mannose or teicoplanin at 56 h, compared with 70% for the normal saline treated mice at the same time point (P < 0.05). This in vivo study shows 'accelerated progression of infection' for Candida-inoculated mice exposed to mannose or teicoplanin compared to those given normal saline. Further, protein polyacrylamide gel electrophoresis studies suggested a potential MBL-drug interaction which may attenuate complement activation, opsonization and phagocytosis.
Asunto(s)
Antibacterianos/administración & dosificación , Candida albicans/inmunología , Candidiasis/inmunología , Lectina de Unión a Manosa/inmunología , Manosa/administración & dosificación , Teicoplanina/administración & dosificación , Animales , Antibacterianos/química , Antibacterianos/metabolismo , Candida albicans/metabolismo , Candidiasis/microbiología , Candidiasis/mortalidad , Interacciones Huésped-Patógeno , Humanos , Manosa/metabolismo , Lectina de Unión a Manosa/metabolismo , Ratones , Ratones Endogámicos BALB C , Unión Proteica , Sobrevida , Teicoplanina/química , Teicoplanina/metabolismoRESUMEN
OBJECTIVES: Amphotericin B (AmB) is a drug of choice for treatment of disseminated fungal infections, but its use is often associated with severe adverse effects. Our observation that generic formulations of AmB contain multiple polyene components led us to propose that removal of other polyenes would yield a high purity AmB (AmBHP) with an improved therapeutic index. METHODS: To test that premise, AmBHP was first isolated from generic AmB by semi-preparative reverse phase high-pressure liquid chromatography and then its effects were compared in vitro and in vivo with those of commercial AmB formulations. RESULTS: AmBHP proved to be as active as generic AmB against Candida albicans in vitro and as efficacious as both generic and lipid-complexed AmB in a Candida-infected mouse model. AmBHP appeared to be less toxic to human THP-1 monocytic cells than was generic AmB at low concentrations (<2 microM), as indicated by exclusion of Trypan Blue and incorporation of [(3)H]thymidine. At higher concentrations, effects of AmBHP and generic AmB (Pharma-Tek AmB, PTAmB) on thymidine incorporation and cytosolic calcium concentration were similar. General toxicity to AmBHP in vivo, as indicated by its apparent LD(50) and survival of Candida-infected mice, was roughly twofold less than that to generic or lipid-complexed AmB. Likewise, AmBHP decreased mean glomerular filtration rate about half as much as did a 10-fold lower dose of PTAmB. CONCLUSIONS: Taken together, these data indicate that AmBHP may represent a refinement of currently marketed AmB formulations, offering equal, if not better, efficacy with less toxicity.
Asunto(s)
Anfotericina B/química , Antifúngicos/química , Candida albicans/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Medicamentos Genéricos/química , Polienos/análisis , Anfotericina B/farmacología , Anfotericina B/uso terapéutico , Anfotericina B/toxicidad , Animales , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Antifúngicos/toxicidad , Candidiasis/microbiología , Candidiasis/mortalidad , Línea Celular , Cromatografía Líquida de Alta Presión , Femenino , Humanos , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Monocitos , Polienos/aislamiento & purificación , Ratas , Ratas Sprague-Dawley , Organismos Libres de Patógenos EspecíficosRESUMEN
BACKGROUND: Secondary, "reactive," thrombocytosis has been attributed to bacterial infection and treatment with multiple pharmaceuticals and may be associated with an increase in the incidence of gastrointestinal tract bleeding and thrombotic events (eg, stroke). OBJECTIVE: To characterize the dynamics of thrombocytosis in patients with candidemia receiving antifungal therapy. METHODS: We initiated a retrospective observational description of patients with candidemia who were treated with antifungal agents. A total of 108 patients diagnosed with candidemia between August 1995 and September 2003 at our teaching hospital were enrolled. Three groups (candidemia with antifungal therapy, candidemia without antifungal therapy, antifungal therapy without candidemia) of patients >18 years of age were evaluated for the presence of thrombocytosis. Platelet administration, pharmacologic or pathologic contributors to thrombocytosis, and other pertinent details related to an elevation of platelet counts were scrutinized. RESULTS: Reactive thrombocytosis was observed in approximately 10% of treated patients with candidemia. Within the subgroup developing reactive thrombocytosis, life-threatening thrombotic complications were uncommon. Mean baseline platelet counts were 393 x 10(3)/mm3, with a mean peak (695 x 10(3)/mm3) occurring an average of 13 days after initiation of therapy. All patients had resolution within 7 days after therapy. The maximum peak (1056 x 10(3)/mm3) was observed in a patient after 14 days of antifungal therapy. The onset of thrombocytosis in this patient was 4 days and lasted 4 days after therapy. CONCLUSIONS: Reactive thrombocytosis occurs during treatment of candidemia. The causative agent (drug vs disease), the risk associated with this reaction, and evaluation of treatment need to be elucidated by a larger epidemiologic study or controlled, prospective clinical trial.
Asunto(s)
Antifúngicos/efectos adversos , Antifúngicos/uso terapéutico , Candidiasis/complicaciones , Candidiasis/tratamiento farmacológico , Trombocitosis/inducido químicamente , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recuento de Plaquetas , Estudios Retrospectivos , Factores de Riesgo , Trombocitosis/sangre , Trombocitosis/epidemiologíaRESUMEN
OBJECTIVE: To review the pharmacology, in vitro susceptibility, pharmacokinetics, clinical efficacy, and adverse effects of voriconazole, a triazole antifungal agent. DATA SOURCES: A MEDLINE search, restricted to English language, was conducted from 1990 to June 2002. Supplementary sources included program abstracts from the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America from 1996 to 2001 and manufacturer information available through the Food and Drug Administration's Web site. DATA EXTRACTION: All published and unpublished trials and abstracts citing voriconazole were selected. DATA SYNTHESIS: Voriconazole has shown in vitro activity against many yeasts and a variety of mold and dermatophyte isolates. Voriconazole can be administered either orally or parenterally. It exhibits good oral bioavailability, wide tissue distribution including distribution into the central nervous system, and hepatic metabolism. Drug interactions occur through inhibition of the CYP2C9, CYP2C19, and CYP3A4 isoenzymes, resulting in alterations in kinetic parameters of either voriconazole or the interacting agent. Efficacy has been illustrated in open, noncomparative studies of aspergillosis in immunocompromised patients. Human case reports describe successful treatment of rare fungal pathogens. The most commonly reported adverse events include visual disturbances and elevations in liver function tests. CONCLUSIONS: Voriconazole is at least as effective as amphotericin B in the treatment of acute invasive aspergillosis in immunocompromised patients. It has similar efficacy as fluconazole in treatment of esophageal candidiasis. Voriconazole did not achieve statistical non-inferiority to liposomal amphotericin B for empirical therapy in patients with neutropenia and persistent fever, diminishing enthusiasm for use in this indication until additional trials are completed. Based on case reports and in vitro efficacy, voriconazole may prove to be a clinically useful agent in the treatment of other fungal disease.
Asunto(s)
Antifúngicos/uso terapéutico , Micosis/tratamiento farmacológico , Pirimidinas/uso terapéutico , Triazoles/uso terapéutico , Antifúngicos/farmacocinética , Antifúngicos/farmacología , Esquema de Medicación , Interacciones Farmacológicas , Formularios Farmacéuticos como Asunto , Humanos , Tiempo de Internación/economía , Micosis/prevención & control , Pirimidinas/farmacocinética , Pirimidinas/farmacología , Ensayos Clínicos Controlados Aleatorios como Asunto , Triazoles/farmacocinética , Triazoles/farmacología , VoriconazolRESUMEN
Aeromonas hydrophila infection has been described as the cause of necrotizing fasciitis in patients with suppressed immune systems, burns, or trauma in an aquatic setting. We report a case in which severe necrotizing fasciitis involving hand, arm, chest, and lateral side of trunk, along with toxic shock, developed after the patient was bitten by a venomous snake. Mixed aerobic and anaerobic bacteria, including A hydrophila, were isolated from the wound culture. The patient was treated with antivenom, a diuretic regimen, broad spectrum antibiotics, and 18 separate surgical procedures. After the application of skin grafts, the wound completely healed. This case illustrates that a venomous snakebite may result in infection with A hydrophila and can cause severe necrotizing fasciitis. Early and aggressive surgical intervention should be implemented as soon as the necrotizing fasciitis is diagnosed.
Asunto(s)
Aeromonas hydrophila , Colubridae , Fascitis Necrotizante/etiología , Fascitis Necrotizante/cirugía , Infecciones por Bacterias Gramnegativas/etiología , Infecciones por Bacterias Gramnegativas/cirugía , Mordeduras de Serpientes/complicaciones , Adulto , Animales , Desbridamiento , Humanos , Masculino , Trasplante de Piel , Mordeduras de Serpientes/terapiaRESUMEN
Amphotericin B (AMB) is an antifungal agent that possesses immunomodulatory properties that may contribute to its infusion-related toxicity and activity. It has previously been shown to induce the expression of genes encoding the cytokines interleukin (IL)-1 beta and tumour necrosis factor (TNF)-alpha and the chemokines IL-8 and macrophage inflammatory protein (MIP)-1 beta in the human monocytic cell line THP-1. In an effort to identify additional AMB-responsive genes, the gene expression profiles of both THP-1 cells and human peripheral blood mononuclear cells (hPBMCs) on exposure to AMB were assessed using cDNA microarray analysis. In addition to genes known to be AMB responsive, we found the genes encoding IL-1 alpha and MIP-1 alpha to be AMB responsive in both THP-1 cells and hPBMCs. Increases in MIP-1 alpha and MIP-1 beta were also observed in the supernatants of hPBMCs exposed to AMB. The expression of several genes in response to AMB was unique to either cell type. Furthermore, variability in gene expression in hPBMCs was observed between donors. These genes and respective gene products may have significance in the infusion-related toxicity and activity of AMB.